» Articles » PMID: 24170556

Overweight, Obesity and Endometrial Cancer Risk: Results from a Systematic Review and Meta-analysis

Overview
Specialties Biochemistry
Oncology
Date 2013 Oct 31
PMID 24170556
Citations 48
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Findings from recent studies suggest that obesity may be associated with an increased risk of endometrial cancer, but several earlier studies were less conclusive. Here we strive to estimate this relationship in a meta-analysis of published data.

Methods: We searched Pubmed and Embase for studies on body mass index and the risk of endometrial cancer, published from 1989 to 2011. Data were independently extracted and analyzed using random or fixed effects meta-analysis depending on the degree of heterogeneity.

Results: Seven cohort studies and 11 case-control studies were included in the meta-analysis. Overall, the conditions of excess body weight ([EBW] defined as body mass index [BMI] ≥25 kg/m²), obesity (BMI ≥30 kg/m²) and overweight (25< BMI <30 kg/m²) were associated with an increased risk of endometrial cancer (relative risk [RR] for EBW=1.62, 95% confidence interval [CI], 1.39-1.89; for obesity RR=2.54, 95% CI, 2.11-3.06; for overweight RR=1.32, 95% CI, 1.16-1.50). Subgroup analyses showed that the positive associations were independent of study design, geographic locations, self-reported BMI, alcohol use, smoking habit, history of diabetes, hormone therapy, age at menarche, age at menopause, parity, and age at first full term pregnancy. However, there was no statistically significant association between EBW and endometrial cancer risk for measured BMI (for EBW RR=1.29, 95% CI, 0.66-2.53).

Conclusions: The findings from this meta-analysis strongly support that the conditions of EBW, overweight, and obesity are all associated with an increased risk of endometrial cancer. Also, the strength of the association increases with increasing BMI.

Citing Articles

Impact of Lifestyle Interventions on Gynecologic Cancers: Beyond Diet and Exercise.

McKenzie N, Ahmad S Am J Lifestyle Med. 2024; 18(1):7-20.

PMID: 39184272 PMC: 11339763. DOI: 10.1177/15598276221123764.


Small molecule targeted therapies for endometrial cancer: progress, challenges, and opportunities.

Yang F, Zhao T, Milaneh S, Zhang C, Xiang D, Wang W RSC Med Chem. 2024; 15(6):1828-1848.

PMID: 38911148 PMC: 11187550. DOI: 10.1039/d4md00089g.


Endometrial Cancer Risk Among Germline / Pathogenic Variant Carriers: Review of Our Current Understanding and Next Steps.

Sorouri K, Lynce F, Feltmate C, Davis M, Muto M, Konstantinopoulos P JCO Precis Oncol. 2023; 7:e2300290.

PMID: 38061009 PMC: 10715772. DOI: 10.1200/PO.23.00290.


Incessant ovulation: a review of its importance in predicting cancer risk.

Cramer D Front Oncol. 2023; 13:1240309.

PMID: 37869082 PMC: 10588628. DOI: 10.3389/fonc.2023.1240309.


ENDOMETRIAL CARCINOMA: THE INTERPLAY OF GENETICS AND HORMONES.

Ellenson L Trans Am Clin Climatol Assoc. 2023; 133:274-282.

PMID: 37701602 PMC: 10493730.